文献速递肿瘤 PET/CT核素与放射性配体治疗

新型雄激素受体信号抑制剂对去势抵抗性前列腺癌患者PSMA PET信号强度的影响:一项前瞻性探索性连续影像研究

Effects of novel androgen receptor signaling inhibitors on PSMA PET signal intensity in patients with castrate-resistant prostate cancer: a prospective exploratory serial imaging study.
PubMed 文献 · EJNMMI Res · 2023-10-30

本前瞻性探索性研究纳入9例起始雄激素受体信号抑制剂(ARSi)的转移性去势抵抗性前列腺癌(mCRPC)患者,在基线、ARSi后1周和3个月行68Ga-PSMA-11全身PET/CT及PSA检测。1年时6/9(66%)患者记录到不良结局;PSA、PSMA-VOL、SUVmean和SUVmax在1周时分别变化-12%、+5%、+3%、+10%,3个月时分别变化-42%、-16%、-15%、-17%。结论认为1周时WB-PSMA PET所测PSMA表达未见显著调节。

要点

  • 9例mCRPC患者起始ARSi后1周,PSMA-VOL、SUVmean、SUVmax分别变化+5%、+3%、+10%。
  • 3个月时PSA、PSMA-VOL、SUVmean、SUVmax分别变化-42%、-16%、-15%、-17%。
  • 1年时6/9(66%)患者记录到不良结局,1周时WB-PSMA PET所测PSMA表达未见显著调节。

核心结论

  • 涉及9例起始ARSi的mCRPC患者的前瞻性试验未显示1周时WB-PSMA PET所测PSMA表达有显著调节。

研究设计与样本

  • 前瞻性纳入起始ARSi的转移性去势抵抗性前列腺癌(mCRPC)患者,行系列PSA检测及基线、ARSi后1周和3个月的68Ga-PSMA-11全身PET/CT(WB-PSMA PET)。
  • 因入组率低,研究在达到30例招募目标前关闭,最终纳入9例患者。

主要发现

  • 1年时9例中6例(66%)记录到不良结局。
  • 9/9例患者完成1周PSMA PET,5/9例完成3个月PSMA PET。
  • PSA、PSMA-VOL、SUVmean和SUVmax在1周时分别变化-12%、+5%、+3%和+10%。
  • PSA、PSMA-VOL、SUVmean和SUVmax在3个月时分别变化-42%、-16%、-15%和-17%。

局限性

  • 因入组率低,研究在达到30例招募目标前关闭,最终纳入9例患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: PSMA expression is influenced by hormonal status. We evaluated changes in PSA and whole-body 68Ga-PSMA-11 PET/CT (WB-PSMA PET) after initiation of androgen receptor signaling inhibitors (ARSi). METHODS: Prospectively enrolled patients with metastatic castration-resistant prostate cancer (mCRPC) initiating ARSi underwent serial PSA measurements and WB-PSMA PET at baseline, 1-week, and 3-months post-ARSi. We correlated WB-PSMA PET metrics and PSA kinetics after ARSi to 1-year clinical outcome. RESULTS: Due to low enrollment rate, the study was closed before reaching the recruitment goal of 30 patients. Nine patients were enrolled. At 1-year, unfavorable outcome was documented in 6/9 (66%) patients. Nine/9 patients completed PSMA PET at 1-week, 5/9 at 3-months. Changes in PSA, PSMA-VOL, SUVmean and SUVmax were - 12%, + 5%, + 3%, and + 10% at 1-week, - 42%, - 16%, - 15% and - 17% at 3-months, respectively. CONCLUSIONS: Our prospective trial involving 9 mCRPC patients initiating ARSi did not show significant modulation of PSMA expression measured on WB-PSMA PET at 1-week. This study was registered on clinicaltrials.gov (NCT04279561).

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Sonni I, Gafita A, Unterrainer LM, et al. Effects of novel androgen receptor signaling inhibitors on PSMA PET signal intensity in patients with castrate-resistant prostate cancer: a prospective exploratory serial imaging study. EJNMMI Res. 2023. PMID: 37902861. doi:10.1186/s13550-023-01048-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。